BG106276A - Диаминотиазоли и употребата им за инхибиране на протеин кинази - Google Patents

Диаминотиазоли и употребата им за инхибиране на протеин кинази Download PDF

Info

Publication number
BG106276A
BG106276A BG106276A BG10627602A BG106276A BG 106276 A BG106276 A BG 106276A BG 106276 A BG106276 A BG 106276A BG 10627602 A BG10627602 A BG 10627602A BG 106276 A BG106276 A BG 106276A
Authority
BG
Bulgaria
Prior art keywords
formula
group
aryl
amino
substituted
Prior art date
Application number
BG106276A
Other languages
Bulgarian (bg)
English (en)
Inventor
Shao CHU
Larry ALEGRIA
Steven Bender
Suzanne BENEDICT
Allen Borchardt
Robert Kania
Mitchell NAMBU
Anna Tempczyk-Russell
Sepehr Sarshar
Dilip Bhumralkar
Zhengwei Peng
Yi Yang
Original Assignee
Agouron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc. filed Critical Agouron Pharmaceuticals, Inc.
Publication of BG106276A publication Critical patent/BG106276A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG106276A 1999-06-04 2002-01-03 Диаминотиазоли и употребата им за инхибиране на протеин кинази BG106276A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13781099P 1999-06-04 1999-06-04
PCT/US2000/015188 WO2000075120A1 (en) 1999-06-04 2000-06-02 Diaminothiazoles and their use for inhibiting protein kinases

Publications (1)

Publication Number Publication Date
BG106276A true BG106276A (bg) 2002-10-31

Family

ID=22479135

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106276A BG106276A (bg) 1999-06-04 2002-01-03 Диаминотиазоли и употребата им за инхибиране на протеин кинази

Country Status (34)

Country Link
US (1) US6620828B2 (xx)
EP (1) EP1181283B1 (xx)
JP (1) JP2003501420A (xx)
KR (1) KR20020015333A (xx)
CN (1) CN1359380A (xx)
AP (1) AP2001002341A0 (xx)
AT (1) ATE288424T1 (xx)
AU (1) AU778071B2 (xx)
BG (1) BG106276A (xx)
BR (1) BR0011585A (xx)
CA (1) CA2371158A1 (xx)
CZ (1) CZ20014213A3 (xx)
DE (1) DE60017894T2 (xx)
EA (1) EA200101268A1 (xx)
EE (1) EE200100659A (xx)
ES (1) ES2234628T3 (xx)
HR (1) HRP20020008A2 (xx)
HU (1) HUP0202897A3 (xx)
IL (1) IL146094A0 (xx)
IS (1) IS6183A (xx)
MA (1) MA25530A1 (xx)
MX (1) MXPA01012483A (xx)
NO (1) NO20015045L (xx)
NZ (1) NZ514881A (xx)
OA (1) OA11959A (xx)
PE (1) PE20010211A1 (xx)
PL (1) PL352714A1 (xx)
SK (1) SK17302001A3 (xx)
SV (1) SV2002000096A (xx)
UA (1) UA71971C2 (xx)
UY (1) UY26190A1 (xx)
WO (1) WO2000075120A1 (xx)
YU (1) YU85601A (xx)
ZA (1) ZA200108291B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
IL135574A0 (en) * 1997-10-27 2001-05-20 Agouron Pharma Substituted 4-amino-thiazol-2-yl compounds as cdk inhibitors
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
IL144910A0 (en) 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
ATE318812T1 (de) 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
IL159086A0 (en) * 2001-06-08 2004-05-12 Cytovia Inc 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
CA2474322A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US6818663B2 (en) * 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
CN100491374C (zh) 2002-08-02 2009-05-27 Ab科学公司 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
RU2337682C2 (ru) 2002-11-01 2008-11-10 Такеда Фармасьютикал Компани Лимитед Средство для профилактики или лечения невропатии
EP1597256A1 (en) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
ES2926542T3 (es) 2003-04-11 2022-10-26 Ptc Therapeutics Inc Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para supresión de mutaciones finalizadoras y el tratamiento de enfermedades
EP1618133A1 (en) * 2003-04-17 2006-01-25 Pfizer Inc. Crystal structure of vegfrkd: ligand complexes and methods of use thereof
EP1644323B1 (en) * 2003-07-07 2015-03-18 Georgetown University Histone deacetylase inhibitors and methods of use thereof
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
PL1680140T3 (pl) * 2003-10-16 2011-11-30 Imclone Llc Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
BRPI0506749A (pt) 2004-01-12 2007-05-22 Applied Research Systems derivados de tiazol e uso dos mesmos
WO2005108370A1 (ja) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
EP1773761A1 (en) * 2004-07-12 2007-04-18 Merck & Co., Inc. Histone deacetylase inhibitors
EP1888573A1 (en) 2005-05-24 2008-02-20 Laboratoires Serono S.A. Thiazole derivatives and use thereof
BRPI0610341A2 (pt) 2005-05-24 2010-06-15 Serono Lab derivados de tiazol e uso dos mesmos
SI1945632T1 (sl) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
CN103214450B (zh) * 2005-12-28 2016-10-05 弗特克斯药品有限公司 作为atp-结合盒转运蛋白调节剂的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物
AU2012244242B2 (en) * 2005-12-28 2015-05-21 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7514566B2 (en) * 2006-01-18 2009-04-07 Amgen, Inc. Thiazole compounds and methods of use
CN101384568B (zh) * 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
JP5369257B2 (ja) * 2006-02-15 2013-12-18 アッヴィ・インコーポレイテッド 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびそれらの糖尿病、肥満および代謝症候群での使用
SG170819A1 (en) 2006-03-30 2011-05-30 Ptc Therapeutics Inc Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
CA2654898A1 (en) * 2006-07-07 2008-10-01 Boehringer Ingelheim International Gmbh New chemical compounds
US7879856B2 (en) 2006-12-22 2011-02-01 Rigel Pharmaceuticals, Inc. Diaminothiazoles useful as Axl inhibitors
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
US20100240657A1 (en) * 2007-07-02 2010-09-23 Boehringer Ingelheim International Gmbh Chemical compounds
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
JP2010533715A (ja) 2007-07-17 2010-10-28 アムジエン・インコーポレーテツド 複素環系ｐｋｂ調節剤
WO2009076142A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
WO2009073757A1 (en) 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP2231625A4 (en) * 2007-12-13 2010-12-29 Glaxosmithkline Llc KINASE INHIBITORS BASED ON THIAZOLE AND OXAZOLE
CA3039943C (en) 2008-02-28 2021-07-13 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
UA103319C2 (xx) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Сполуки бензенсульфонамідтіазолу та -оксазолу$соединения бензенсульфонамидтиазола и -оксазола
PE20110294A1 (es) 2008-09-29 2011-05-26 Boehringer Ingelheim Int Compuestos heterociclicos como inhibidores de enzimas de senal especifica
US8546433B2 (en) 2009-01-16 2013-10-01 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
US8637557B2 (en) 2009-10-19 2014-01-28 Taisho Pharmaceutical Co., Ltd Aminothiazole derivative
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
CA2795804C (en) 2010-04-07 2021-10-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
ES2605388T3 (es) 2012-04-26 2017-03-14 Ono Pharmaceutical Co., Ltd. Compuesto inhibidor de Trk
MX353336B (es) 2013-02-19 2018-01-09 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CA3174516A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
PT3221692T (pt) 2014-11-18 2021-09-10 Vertex Pharma Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
MX2018005361A (es) 2015-10-30 2018-06-07 Ptc Therapeutics Inc Metodos para tratar epilepsia.
US11001564B2 (en) * 2016-09-13 2021-05-11 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
CN111233786B (zh) * 2020-02-04 2021-11-26 中国人民解放军军事科学院军事医学研究院 含五元杂环的苯磺酰胺类化合物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273062C (de) 1912-04-19 1914-04-20 Deylen Sohn Firma Vorrichtung zum Schränken von Plattenzündspänen
AU558132B2 (en) 1981-05-27 1987-01-22 Labatt Brewing Co. Ltd. Malt sterilisation with hydrogen peroxide
WO1986005779A1 (en) 1985-04-03 1986-10-09 Yamanouchi Pharmaceutical Co., Ltd. Phenylene derivatives
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
WO1993019052A1 (en) 1992-03-24 1993-09-30 Merck Sharp & Dohme Limited 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
CN1165482A (zh) 1994-11-10 1997-11-19 科西雷佩蒂斯公司 用作蛋白激酶抑制剂的吡唑药物组合物
BR9607016A (pt) 1995-02-02 1997-10-28 Smithkline Beecham Plc Derivados de indol como antagonísta de receptor 5-ht
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5705499A (en) 1995-10-06 1998-01-06 Boehringer Ingelheim Pharmaceuticals, Inc. 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
DE69734149T2 (de) 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
ES2168581T3 (es) 1996-06-27 2002-06-16 Pfizer Derivados de indazol sustituidos.
CN1234031A (zh) 1996-09-04 1999-11-03 辉瑞大药厂 吲唑衍生物及其作为磷酸二酯酶(pde)iv型和肿瘤坏死因子(tnf)产生的抑制剂的应用
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
IL135574A0 (en) * 1997-10-27 2001-05-20 Agouron Pharma Substituted 4-amino-thiazol-2-yl compounds as cdk inhibitors
ID24942A (id) 1997-11-04 2000-08-31 Pfizer Prod Inc Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4
ID23921A (id) 1997-11-04 2000-05-25 Pfizer Prod Inc Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
JP2002518380A (ja) * 1998-06-18 2002-06-25 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤
DK1117659T3 (da) 1998-09-29 2004-03-22 Wyeth Corp Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser

Also Published As

Publication number Publication date
HRP20020008A2 (en) 2004-02-29
BR0011585A (pt) 2002-03-19
SK17302001A3 (sk) 2004-01-08
US20020025976A1 (en) 2002-02-28
EP1181283A1 (en) 2002-02-27
PL352714A1 (en) 2003-09-08
UA71971C2 (en) 2005-01-17
ZA200108291B (en) 2002-12-24
CN1359380A (zh) 2002-07-17
DE60017894T2 (de) 2005-12-29
WO2000075120A1 (en) 2000-12-14
EP1181283B1 (en) 2005-02-02
NO20015045D0 (no) 2001-10-17
OA11959A (en) 2006-04-17
IS6183A (is) 2001-11-29
EA200101268A1 (ru) 2002-06-27
NO20015045L (no) 2002-02-04
AP2001002341A0 (en) 2001-12-31
HUP0202897A3 (en) 2004-12-28
CZ20014213A3 (cs) 2002-04-17
SV2002000096A (es) 2002-06-07
JP2003501420A (ja) 2003-01-14
HUP0202897A2 (hu) 2002-12-28
NZ514881A (en) 2003-10-31
MA25530A1 (fr) 2002-10-01
US6620828B2 (en) 2003-09-16
KR20020015333A (ko) 2002-02-27
AU778071B2 (en) 2004-11-11
UY26190A1 (es) 2000-12-29
DE60017894D1 (de) 2005-03-10
YU85601A (sh) 2004-09-03
ES2234628T3 (es) 2005-07-01
AU5725400A (en) 2000-12-28
MXPA01012483A (es) 2002-07-30
PE20010211A1 (es) 2001-03-16
ATE288424T1 (de) 2005-02-15
IL146094A0 (en) 2002-07-25
CA2371158A1 (en) 2000-12-14
EE200100659A (et) 2003-02-17

Similar Documents

Publication Publication Date Title
BG106276A (bg) Диаминотиазоли и употребата им за инхибиране на протеин кинази
US6462069B2 (en) Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases
KR20200032154A (ko) Nlrp 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
EP1813606A1 (en) Amide compound
JP2018500343A (ja) Ｃｆｔｒ活性を増加するための化合物、組成物及び方法
CN101790526A (zh) 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
TW201930315A (zh) 具抗b型肝炎病毒(hbv)活性之新穎高活性胺基-噻唑取代之吲哚-2-甲醯胺
JP2011098984A (ja) Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのイソチアゾールジオキシド
CN111263756A (zh) Rad51抑制剂
MX2013008629A (es) Inhibidores de histona desacetilasa y composiciones y metodos para su uso.
EP2107054A1 (en) Antiproliferative compounds and therapeutic uses thereof
US20210115029A1 (en) Pyridyl benzothiophenes as kinase inhibitors
CA2411928A1 (en) Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclindependent kinases
CN102459251A (zh) 作为白三烯a4水解酶的调节剂的具有两个稠合双环杂芳基部分的化合物
TW202330537A (zh) Wee1抑制劑及其製備和用途
BRPI0714535A2 (pt) composto, pelo menos uma entidade quÍmica, composiÇço farmacÊutica, mÉtodo, formulaÇço farmcÊutica embalda e uso
WO2023146513A1 (en) Compounds and methods of use thereof
NZ723972B2 (en) Hepatitis b core protein allosteric modulators
NZ723972A (en) Hepatitis b core protein allosteric modulators
NZ613087B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof